JP2005525365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525365A5 JP2005525365A5 JP2003572988A JP2003572988A JP2005525365A5 JP 2005525365 A5 JP2005525365 A5 JP 2005525365A5 JP 2003572988 A JP2003572988 A JP 2003572988A JP 2003572988 A JP2003572988 A JP 2003572988A JP 2005525365 A5 JP2005525365 A5 JP 2005525365A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- alkynyl
- alkyl
- alkenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 claims 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 claims 2
- 229940121367 non-opioid analgesics Drugs 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 108010025083 TRPV1 receptor Proteins 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- -1 acyclic hydrocarbon Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36017202P | 2002-03-01 | 2002-03-01 | |
| US41108402P | 2002-09-17 | 2002-09-17 | |
| PCT/US2003/006107 WO2003074520A1 (en) | 2002-03-01 | 2003-02-28 | Thiadiazolylpiperazine derivatives useful for treating or preventing pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525365A JP2005525365A (ja) | 2005-08-25 |
| JP2005525365A5 true JP2005525365A5 (https=) | 2006-04-06 |
| JP4663984B2 JP4663984B2 (ja) | 2011-04-06 |
Family
ID=27791632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572988A Expired - Fee Related JP4663984B2 (ja) | 2002-03-01 | 2003-02-28 | 疼痛の治療または防止に有用なチアジアゾリルピペラジン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6974818B2 (https=) |
| EP (1) | EP1487829B1 (https=) |
| JP (1) | JP4663984B2 (https=) |
| AT (1) | ATE375341T1 (https=) |
| AU (1) | AU2003225617A1 (https=) |
| CY (1) | CY1107850T1 (https=) |
| DE (1) | DE60316779T2 (https=) |
| DK (1) | DK1487829T3 (https=) |
| ES (1) | ES2295609T3 (https=) |
| PT (1) | PT1487829E (https=) |
| WO (1) | WO2003074520A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060446A1 (fr) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| CA2509616A1 (en) * | 2002-12-13 | 2004-07-01 | Neurogen Corporation | Combination therapy for the treatment of pain |
| AU2003301184A1 (en) * | 2002-12-20 | 2004-07-22 | Dynogen Pharmaceuticals Inc | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| US7524515B2 (en) | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
| AU2004224322A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| US20050009841A1 (en) * | 2003-07-11 | 2005-01-13 | Zheng Guo Zhu | Novel amides useful for treating pain |
| US7129235B2 (en) | 2003-07-11 | 2006-10-31 | Abbott Laboratories | Amides useful for treating pain |
| EP1867644B1 (en) * | 2003-07-24 | 2009-05-20 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| DE602004017316D1 (de) * | 2003-07-24 | 2008-12-04 | Euro Celtique Sa | Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen |
| WO2005012287A1 (en) * | 2003-08-01 | 2005-02-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| PL1664041T3 (pl) * | 2003-09-22 | 2008-12-31 | Euro Celtique Sa | Przydatne do leczenia bólu związki fenylowo-karboksyamidowe |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
| CN101039927A (zh) * | 2004-09-09 | 2007-09-19 | 财团法人乙卯研究所 | 5－羟色胺5－ht3受体激动剂 |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| EP1937252B1 (en) * | 2005-09-19 | 2017-10-25 | Neuronascent, Inc. | Compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| AU2013211455B2 (en) * | 2005-09-19 | 2017-12-07 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| EP1957112A2 (en) * | 2005-11-21 | 2008-08-20 | Pietro Paolo Sanna | Role of proteoglycans in drug dependence |
| DE102005062986A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| CA2685266C (en) | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| US20100267682A1 (en) * | 2007-11-09 | 2010-10-21 | Novartis Ag | Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| NZ593090A (en) * | 2008-11-13 | 2013-06-28 | Link Medicine Corp | Azaquinolinone derivatives and uses thereof |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US8921373B2 (en) | 2010-06-22 | 2014-12-30 | Shionogi & Co., Ltd. | Compounds having TRPV1 antagonistic activity and uses thereof |
| JP6130827B2 (ja) | 2011-05-17 | 2017-05-17 | 塩野義製薬株式会社 | ヘテロ環化合物 |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| JP6210988B2 (ja) | 2011-09-19 | 2017-10-11 | オレクソ・アクチエボラゲット | オピオイド依存を治療するための新規乱用耐性医薬組成物 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| UA124972C2 (uk) | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| US5198459A (en) * | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
| DE3822792C2 (de) * | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5075341A (en) * | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| US6204284B1 (en) * | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US5232934A (en) * | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5556837A (en) * | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
| US5762925A (en) * | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
| WO1999009140A1 (en) | 1997-08-20 | 1999-02-25 | The Regents Of The University Of California | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
| EP0943683A1 (en) | 1998-03-10 | 1999-09-22 | Smithkline Beecham Plc | Human vanilloid receptor homologue Vanilrep1 |
| ATE321042T1 (de) * | 1998-12-14 | 2006-04-15 | Astellas Pharma Inc | Piperazin-derivate |
| CA2361179A1 (en) * | 1999-03-03 | 2000-09-08 | American Home Products Corporation | New diazole derivatives as serotonergic agents |
| GB9907097D0 (en) | 1999-03-26 | 1999-05-19 | Novartis Ag | Organic compounds |
| US6109269A (en) * | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
| EP1301484A2 (en) | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
| CA2417507A1 (en) | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| ATE328868T1 (de) * | 2000-08-21 | 2006-06-15 | Pacific Corp | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten |
| MY138086A (en) | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
| HUP0500200A2 (hu) | 2002-01-17 | 2005-07-28 | Neurogen Corporation | Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények |
| AU2003245773A1 (en) | 2002-02-15 | 2003-09-04 | Glaxo Group Limited | Vanilloid receptor modulators |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20030158188A1 (en) * | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
-
2003
- 2003-02-27 US US10/374,863 patent/US6974818B2/en not_active Expired - Lifetime
- 2003-02-28 AT AT03743718T patent/ATE375341T1/de active
- 2003-02-28 JP JP2003572988A patent/JP4663984B2/ja not_active Expired - Fee Related
- 2003-02-28 DE DE60316779T patent/DE60316779T2/de not_active Expired - Lifetime
- 2003-02-28 DK DK03743718T patent/DK1487829T3/da active
- 2003-02-28 PT PT03743718T patent/PT1487829E/pt unknown
- 2003-02-28 AU AU2003225617A patent/AU2003225617A1/en not_active Abandoned
- 2003-02-28 EP EP03743718A patent/EP1487829B1/en not_active Expired - Lifetime
- 2003-02-28 ES ES03743718T patent/ES2295609T3/es not_active Expired - Lifetime
- 2003-02-28 WO PCT/US2003/006107 patent/WO2003074520A1/en not_active Ceased
-
2005
- 2005-10-07 US US11/246,498 patent/US7342017B2/en not_active Expired - Lifetime
-
2008
- 2008-01-08 CY CY20081100025T patent/CY1107850T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525365A5 (https=) | ||
| JP2005521679A5 (https=) | ||
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| RU2018111439A (ru) | Новое пиразоло[3, 4-d]пиримидиновое соединение или его соль | |
| JP2013533228A5 (https=) | ||
| JP2013500304A5 (https=) | ||
| BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
| JP2012507567A5 (https=) | ||
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| JP2013505946A5 (https=) | ||
| JP2007518805A5 (https=) | ||
| BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
| JP2013512898A5 (https=) | ||
| CN1290504C (zh) | 含有combretastatin和抗癌剂的复合药物 | |
| AR059501A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
| JP2008542444A5 (https=) | ||
| CA2604581A1 (en) | Combinations, methods and compositions for treating cancer | |
| RU2011134283A (ru) | Имидазотиазольные производные, имеющие пролиновую циклическую структуру | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| MX2025005392A (es) | Composicion farmaceutica que comprende un inhibidor de aak1 | |
| RU2009111387A (ru) | Фармацевтические композиции для лечения грибковых инфекций | |
| CA2679047A1 (en) | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | |
| JP2011508779A5 (https=) |